|
| Study name (sponsor) | NCT ID | Number of patients (treatment/controls) | Delivery route | Cell dose (×106) | Follow-up interval (months) | Outcomes | Adverse effect |
|
| Skeletal myoblasts | | | | | | | |
| MAGIC (Genzyme) | NCT00102128 | 67/30 | IM | Low dose: 400
High dose: 800 | 6 | Neutral for LVEF
Reduced LVESV (−9.5%)
Reduced LVEDV from high dose (−13.6%) | Low dose: 4 with ventricular arrhythmias and 5 deaths
High dose: 5 with arrhythmias and 4 deaths |
| CAUSMIC (Mytogen) | NCT00626314 | 12/11 | IM | 30, 100, 300, 600 | 12 | Improved LVEF (12.4%)
Reduced NYHA | 6 with ventricular arrhythmias out of 12 patients |
| SEISMIC (Bioheart) | NCT00375817 | 26/14 | IM | 150–800 | 6 | Neutral for LVEF
Reduced for NYHA
Increased 6 MWD | 12 with ventricular arrhythmias out of 26 patients and 1 death |
| Bone marrow mononuclear cells | | | | | | |
| Janssens et al. (Universitaire Ziekenhuizen Leuven) | NCT00264316 | 33/34 | IC | 304 | 4 | Neutral for LVEF
Reduced infarct size (−28%) | No major adverse events |
| REPAIR-AMI (A. M. Zeiher) | NCT00279175 | 102/102 | IC | 200 | 24 | Improved LVEF (2%)
Reduced LVESV (−1%) | No major adverse events |
| Cardio 133 (German Heart Institute) | NCT00462774 | 30/30 | IM | 5 | 6 | Reduced LVEF (−2.1%)
Neutral LVESV
Neutral LVEDV | No major adverse events |
| FINCELL (University of Oulu) | NCT00363324 | 40/40 | IC | 360 | 6 | Improved LVEF (5%)
Reduced LVESV (−5.7%)
Reduced LVEDV (−1.3%) | No major adverse events |
| MiHeart-AMI (Ministry of Health, Brazil) | NCT00350766 | 150/150 | IC | 100 | 12 | No study results | No study results |
| BOOST (Hannover Medical School) | NCT00224536 | 30/30 | IC | 2000 | 6, 18, 60 | Larger scar: improved LVEF (7.6%)
Smaller scar: reduced LVEF (−6.6%)
Increased LVESV (42%)
Increased LVEDV (29%) | No major adverse events |
| DanCell-CHF (Odense University Hospital) | NCT00235417 | 32/0 | IC | 1st: 650
2nd: 900 | 4, 8, 12 | Neutral for LVEF
Improved LV filling | No major adverse events |
| MYSTAR (Medical University of Vienna) | NCT00384982 | 40/20 | IC/IM | 200 | 3 | Early group: Improved LVEF (3.5%)
Late group: Improved LVEF (3.9%) | No major adverse events |
| BALANCE (University of Düsseldorf) | Reference [46] | 62/62 | IC | 60 | 3, 12, 60 | Improved LVEF (10%)
Reduced LVESV (−4.0%)
Reduced infarct size (−8.2%) | No major adverse events |
| REGENT (Silesian School of Medicine) | NCT00316381 | 160/40 | IC | 200 | 6 | Neutral for LVEF | No major adverse events |
| STAR-heart (University of Düsseldorf) | Reference [68] | 191/200 | IC | 66 | 3, 12, 60 | Improved LVEF (6.2%)
Reduced LVESV (−12.9%)
Reduced LVEDV (−5.1%) | No major adverse events |
| AMRS (Emory University) | NCT00313339 | 28/22 | IC | 5, 10, 15 | 6 | Improved LVEF (2.1%)
Reduced infarct size (−5.5%) | No major adverse events |
| TOPCARE-AMI (Johann Wolfgang Goethe University Hospital) | NCT00289822 | 29/30 | IC | 5.5 | 60 | Improved LVEF (11.6%)
Reduced LVESV (−16.3%)
Reduced LVEDV (−49.5%) | No major adverse events |
| Hu et al. (China National Center for Cardiovascular Diseases) | NCT00395811 | 31/29 | IC | 10–700 | 6 | Improved LVEF (5.7%)
Reduced LVESV (−14.8%)
Reduced LVEDV (−10.7%) | No major adverse events |
| BONAMI (Nantes University Hospital) | NCT00200707 | 52/49 | IC | 100 | 12 | Neutral for LVEF
Neutral for infarct size | 1 death in cell treatment group after 1 month |
| PERFECT (Miltenyi Biotec GmbH) | NCT00950274 | 41/40 | IM | 0.5–5 | 6 | No study results | No study results |
| TIME (The University of Texas Health Science Center, Houston) | NCT00684021 | 43/24 | IC | 150 | 6 | Neutral for LVEF | No major adverse events |
| ASTAMI (Oslo University Hospital) | NCT00199823 | 50/50 | IC | 80 | 3, 6, 12, 36 | Neutral for LVEF
Reduced infarct size (−25%) | No major adverse events |
| SCAMI (University of Ulm) | NCT00669227 | 28/14 | IC | 324 | 6, 12, 24, 36 | 6 months: improved LVEF (4.1%)
12 months: improved LVEF (3.8%)
24 months: improved LVEF (4.5%)
36 months: reduced LVEF (5.6%) | No major adverse events |
| METHOD (Cardiocentro Ticino) | NCT01666132 | 36/18 | IC/IM | 50–500 | 6, 12 | Neutral for LVEF | No major adverse events |
| SWISS-AMI (University of Zurich) | NCT00355186 | 128/64 | IC | 119–153 | 4, 6, 12 | Neutral for LVEF
Reduced LVESV (−9.4%)
Reduced LVEDV (−8.4%)
Reduced infarct size (−4.67%) | No major adverse events |
| TAC-HFT (University of Miami) | NCT00768066 | 19/10 | IM | 100, 200 | 12 | Neutral for infarct size | No major adverse events |
| Helsinki BMMC (Helsinki University) | NCT00418418 | 20/19 | IC | 840 | 12 | Neutral for LVEF
Reduced infarct size (13.1%) | No major adverse events |
| MultiStem (Athersys, Inc.) | NCT00677222 | 19/6 | IC | 20, 50, 100 | 4 | 20 M cells: Improved LVEF (3.9%)
50 M cells: Improved LVEF (13.5%)
100 M cells: Improved LVEF (10.9%) | No major adverse events |
| Hu et al. (Second Affiliated Hospital, School of Medicine, Zhejiang University) | NCT01234181 | 22/14 | IC | 100 | 6, 12 | Neutral for LVEF | No major adverse events |
| Ge et al. (Fudan University) | NCT02425358 | 79/25 | IC | 500 | 12 | 24 after PCI: improved LVEF (4.5%)
3−7 days after PCI: improved LVEF (3.5%)
3−30 days after PCI: improved LVEF (1.3%) | No major adverse events |
| TECAM (TECAM Group) | NCT00984178 | 89/31 | IC | 5 | 12 | Improved LVEF (4%)
Neutral for LVESV
Neutral LVEDV | No major adverse events |
| REGENERATE-AMI (Barts & The London NHS Trust) | NCT00765453 | 55/45 | IC | 59.8 | 3, 12 | Improved LVEF (2.2%)
Reduced infarct size (−33.3%) | No major adverse events |
| | | | | | | | |
| Mesenchymal stem cells | | | | | | |
| Prochymal (Mesoblast International Sàrl) | NCT00114452 | 39/21 | IV | 30–300 | 3, 6, 12 | Improved LVEF (6.7%) | No major adverse events |
| POSEIDON-Pilot (University of Miami) | NCT01087996 | 15/16 (autologous/allogeneic) | IM | 20, 100, 200 | 13 | Neutral for LVEF
20 M cells: Improved LVEF
Reduced infarct size (−33.21%)
Allogeneic: Reduced LVEDV | No major adverse events |
| PROMETHEUS (Joshua M Hare) | NCT00587990 | 6/3 | IM | 20, 200 | 3, 6, 18 | Improved LVEF (9.5%)
Reduced infarct size (−47.5%) | No major adverse events |
| TAC-HFT (University of Miami) | NCT00768066 | 19/10 | IM | 100, 200 | 12 | Neutral for LVEF
Reduced infarct size (−18.9%)
Increased 6 MWD | No major adverse events |
| SEED-MSC (Yonsei University) | NCT01392105 | 30/28 | IC | 72 | 6 | Improved LVEF (5.9%) | No major adverse events |
| Stempeucel (Stempeutics Research Pvt. Ltd.) | NCT00883727 | 10/10 | IV | 200 | 24 | Improved LVEF (2%) | No major adverse events |
| WJ-MSC-AMI (Navy General Hospital, Beijing) | NCT01291329 | 58/57 | IC | 6 | 18 | Improved LVEF (5%)
Reduced LVESV (−22.6%)
Reduced LVEDV (−9.5%) | No major adverse events |
| | | | | | | | |
| Adipose derived mesenchymal stem cells | | | | | | |
| PRECISE (Cytori Therapeutics) | NCT00426868 | 21/6 | IM | 42 | 6, 12, 18 | Neutral for LVEF
Reduced infarct size (−12.8%) | No major adverse events |
| CSCC_ASC (Jkastrup, Denmark) | NCT02387723 | 10 | IM | 100 | 6 | No study results | No study results |
| ATHENA (Cytori Therapeutics) | NCT01556022 | 14/14 | IM | 40 | 6, 12 | No study results | No study results |
| | | | | | | | |
| Cardiac stem cells | | | | | | |
| SCIPIO (University of Louisville) | NCT00474461 | 16/7 | IC | 1 | 4, 12 | Improved LVEF (12.3%)
Reduced infarct size (−30.2% ) | No major adverse events |
| CADUCEUS (Cedars-Sinai Medical Center) | NCT00893360 | 17/8 | IC | 12.5–25 | 6, 12 | Neutral for LVEF
Neutral for LVESV
Neutral for LVEDV
Reduced infarct size (−12.3%) | 4 patients had serious adverse events |
|
